Back to Search
Start Over
Esthesioneuroblastoma: The Princess Margaret Hospital experience
- Source :
- Head & Neck. 30:1607-1614
- Publication Year :
- 2008
- Publisher :
- Wiley, 2008.
-
Abstract
- Background. Esthesioneuroblastoma is rare. The aim of the study was to review our experience and to evaluate the staging system and treatment that best correlates with the patient outcome. Methods. Thirty-nine patients were identified between 1972 and 2006. Results. At presentation 10% had cervical metastases. None had distant metastasis. Five were treated with surgery, 2 with chemotherapy, 1 with radiotherapy, and 30 with surgery and radiation. Local disease control was 82.6% at 5 years. Recur- rence was seen in 33% with local and regional disease recur- rence at 15% and 18%, respectively. The 5- and 10-year overall survival rates were 87.9% and 69.2%, respectively. Dulguerov classification correlated most closely to survival and recurrence. Conclusions. Dulguerov classification best correlates with the patient's outcome. A combined approach is the preferred treat- ment. It makes no difference whether radiotherapy is given pre or postsurgical resection. Recurrence can occur even 15 years after treatment. Therefore, long-term follow-up is essential. V C 2008
- Subjects :
- Adult
Male
medicine.medical_specialty
medicine.medical_treatment
Nose Neoplasms
Esthesioneuroblastoma, Olfactory
Hospital experience
Resection
Hospitals, University
Esthesioneuroblastoma
Humans
Medicine
Aged
Neoplasm Staging
Retrospective Studies
Ontario
Chemotherapy
business.industry
Cancer
Middle Aged
medicine.disease
Survival Analysis
Combined approach
Surgery
Radiation therapy
Treatment Outcome
Otorhinolaryngology
Neck Dissection
Female
Nasal Cavity
Neoplasm Recurrence, Local
business
After treatment
Follow-Up Studies
Subjects
Details
- ISSN :
- 10970347 and 10433074
- Volume :
- 30
- Database :
- OpenAIRE
- Journal :
- Head & Neck
- Accession number :
- edsair.doi.dedup.....61e77d98a43abd9be7078f2463dcd731
- Full Text :
- https://doi.org/10.1002/hed.20920